Visiongain Report Provides Critical Market-led Data on the $76bn Translational Regenerative Medicine Market


LONDON, Mar. 13, 2019 —

Translational Regenerative Medicine Market Forecast 2019-2029

Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 23.3% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in the market with an estimated market share of 57.7% in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you will find 334-page report and you will receive 119 tables and 106 figures – all unavailable elsewhere.

The 334-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Translational Regenerative Medicine market forecasts from 2019-2029

• Global Translational Regenerative Medicine submarket forecasts from 2019-2029 covering:

• Stem Cell Therapies

• Tissue Engineered Products

• Gene Therapies

This study discusses the late-state clinical trials and pipeline as well as market drivers and restraints of each submarket.

• Translational Regenerative Medicine regional and national market forecasts from 2019-2029, covering:

North America: US, Canada

Europe: Germany, France, UK, Italy, Spain, Rest of Europe

Asia-Pacific: China, Japan, India, Rest of Asia-Pacific

Latin America: Brazil, Mexico, Rest of Latin America

Middle East & Africa: GCC Countries, South Africa, Rest of Middle East & Africa

Each regional market is further segmented by sector.

• Forecasts from 2019-2029 of the selected leading products in the Global Translational Regenerative Medicine market:

• Osteocel Plus

• Trinity ELITE

• TEMCELL /Prochymal

• Apligraf

• Dermagraft

• Epifix

• ReCell

• Neovasculgen

• Glybera (alipogene tiparvovec)

• IMLYGIC (talimogene laherparepvec)

• Assessment of the leading companies in the Global Translational Regenerative Medicine market:

• Athersys, Inc.

• Avita Medical

• AxoGen, Inc.

• MEDIPOST Co., Ltd.

• NuVasive

• Astellas Pharma

• Organogenesis Holdings Inc.

• Osiris Therapeutics, Inc.

• Pharmicell Co., Ltd.

• Regenerys Ltd.

• Takeda Pharmaceutical Company Limited

• uniQure N.V. N.V.

• Vericel Corporation

• Information on current developments, current advancements and current key approvals in the field of translational regenerative medicine market.

SWOT and Porter’s Five Force analysis of the translational regenerative medicine market

Visiongain’s study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

To request a report overview of this report please contact Sara Peerun at or refer to our website:

Did you know that we also offer a report add-on service? Email to discuss any customized research needs you may have.

Aastrom Biosciences, Inc.

Abeona Therapeutics Inc.


Ageless Regenerative Institute

Alliqua BioMedical, Inc.




Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud

AnGes MG/ Vical


Arizona Pain Specialists

Assistance Publique Hopitaux De Marseille

Astellas Pharma

Athersys, Inc.

Avita Medical

Axiogenesis AG

AxoGen, Inc.


Bellicum Pharmaceuticals

Benda Pharmaceutical

Biedermann Technologies GmbH & Co. KG

BioCardia, Inc.


bluebird bio

BrainStorm Cell Therapeutics

Bristol-Meyers Squibb

Caladrius Biosciences


Cardio3 BioSciences


Cell Medica

Cellerant Therapeutics

Cellular Dynamics International, Inc.


Chiesi Farmaceutici SpA

Cold Genesys

Cytori Therapeutics

DePuy Mitek

Dimension Therapeutics, Inc.

Fibrocell Science

FUJIFILM Corporation

GE Healthcare


Healeon Medical Inc



Hoffmann-La Roche

Homology Medicines, Inc.

Innovative Cellular Therapeutics (ICT)

Integra LifeSciences



Irvine Scientific

Japan Regenerative Medicine Co., Ltd.

Japan Tissue Engineering Co. Ltd

JCR Pharmaceuticals Co. Ltd.
Jianwu Dai

Johnson & Johnson

Kinetic Concepts Inc

Kite Pharma
Lonza Houston, Inc.





Mesoblast, Ltd.

MidCap Financial Services (MidCap Financial)

MiMedx Group, Inc.

Nasser Aghdami MD., PhD



Ocata Therapeutics


Orchard Therapeutics

Organogenesis Holdings Inc.


Osiris Therapeutics, Inc.

Oxford BioMedica

Pall Corporation

Parcell Laboratories

Pfizer, Inc.


Pharmicell Co., Ltd.

Promethera Biosciences SA

Regen Lab SA

Regenerative Patch Technologies, LLC

Regenerative Sciences, LLC

Regenerys Ltd.



Royan Institute

Sangamo BioSciences


Semma Therapeutics


Shanghai Sunway
Shinya Yamanaka

Siemens Healthineers

Silicon Valley Bank

Skye Orthobiologics

Sobi Partners

Sotex PharmFirm

Spark Therapeutics

StemCells Inc.

Stempeutics Research

Takeda Pharmaceuticals


TissueGene, Inc.

U.S. Stem Cell Inc.

uniQure NV

Universal Cells, Inc.

Vericel Corporation

ViaCyte Inc

Xenetic Biosciences


List of Organisations Mentioned in This Report

Academy Military Medical Science, China

American Diabetes Association

Andalusian Initiative for Advanced Therapies – Fundación Pública Andaluza Progreso y Salud

Arthritis Research UK

Australian Regenerative Medicine Institute

Australian Research Council

Banc de Sang i Teixits

Beijing Cancer Hospital

Brazil Ministry of Health, Ministry of Education

Brazilian Development Bank (BNDES)

British Heart Foundation
Cambridge University Hospitals NHS Foundation Trust

Catalan Institution for Research and Advanced Studies

Center for Biologics Evaluation and Research (CBER)

Center for Devices and Radiological Health (CDRH).

Center for Drug Evaluation and Research (CDER)

Centre Hospitalier René Dubos

Charité University Clinic

China Construction bank

Chinese Academy of Sciences

Committee for Advanced Therapies

Committee for Medicinal Products for Human Use (CHMP)

Department of Health and the Care Quality Commission

Drugs Controller General of India

European Commission

European Group for Blood and Marrow Transplantation

European Medicines Agency

European Patent Office

European Union

Food and Drug Administration (FDA)

Fourth Military Medical University

German National Registry of Blood Stem Cell Donors

Herlev Hospital

House of Lords Science and Technology Committee

Human Fertilisation and Embryology Authority

Human Stem Cell Institute

Innovation in Japan

Institute for Biomedical Research
Kenneth Hargreaves

King Abdullah International Medical Research Centre (KAIMRC)

King Khaled University

King Saud bin Abdulaziz University for Health Sciences (KSAU – HS)

Korea Food and Drug Administration

Kuopio University Hospital
Massachusetts General Hospital (MGH)

Medical Research Council

Ministry of Food and Drug Safety

Ministry of Public Health, Republic of Belarus

Musculoskeletal Transplant Foundation (MTF)
Northwestern University

Nursing Association for the Study of Cutaneous Wounds

Oregon Health and Science University

Pharmaceuticals and Medical Devices Agency (PMDA)

Regenerative Medicines in Europe Project (REMEDiE)

Russian Academy of Medical Sciences

Russian Ministry of Healthcare and Social Development

Servizio Sanitario Nazionale, Italy

Sidney Kimmel Comprehensive Cancer Center

South African Government

South China Research Center for Stem Cell and Regenerative Medicine
Stanford University

State Food and Drug Administration

The University of Texas Health Science Center, Houston

Therapeutics Goods Administration

University College London

University Hospital of Basel, Switzerland
University of California, Los Angeles (UCLA)
University of California, San Francisco (UCSF)

University of Leeds
University of Massachusetts

Wenzhou Medical University

World Bank

Yamaguchi University Hospital

To see a report overview please e-mail Sara Peerun on

SOURCE Visiongain